In a filing, Halozyme Therapeutics Inc revealed its Director JEFFREY HENDERSON acquired Company’s shares for reported $0.85 million on Feb 03 ’25. In the deal valued at $56.64 per share,15,000 shares were bought.
Then, Henderson Jeffrey William sold 10,000 shares, generating $500,060 in total proceeds. Upon selling the shares at $50.01, the Director now owns 43,611 shares.
Before that, JEFFREY HENDERSON bought 10,000 shares. Halozyme Therapeutics Inc shares valued at $477,400 were divested by the Director at a price of $47.74 per share.
Wells Fargo downgraded its Halozyme Therapeutics Inc [HALO] rating to an Equal weight from a an Overweight in a research note published on October 07, 2024; the price target was increased to $62 from $58. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid September from “an Overweight” to “a Neutral”. Piper Sandler also remained covering HALO and has decreased its forecast on June 07, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. TD Cowen started covering the stock on February 29, 2024. It rated HALO as “an Outperform”.
Price Performance Review of HALO
On Monday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock fall -0.64% to $56.28. Over the last five days, the stock has gained 0.75%. Halozyme Therapeutics Inc shares have risen nearly 17.72% since the year began. Nevertheless, the stocks have risen 66.26% over the past one year. While a 52-week high of $65.53 was reached on 01/30/25, a 52-week low of $33.15 was recorded on 01/03/25. SMA at 50 days reached $50.43, while 200 days put it at $51.86.
Levels Of Support And Resistance For HALO Stock
The 24-hour chart illustrates a support level at 55.11, which if violated will result in even more drops to 53.95. On the upside, there is a resistance level at 57.29. A further resistance level may holdings at 58.31. The Relative Strength Index (RSI) on the 14-day chart is 67.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.86, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 28.10%. Stochastics %K at 78.79% indicates the stock is a holding.
How much short interest is there in Halozyme Therapeutics Inc?
A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2025-01-15, growing by 0.62 million shares to a total of 9.41 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 8.79 million shares. There was a rise of 6.55%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 24, 2023 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $61 price target.
